FindTrial
Sign In

Clinical study on the role of secretory autophagy protein HMGB1 in the treatment resistance of temozolomide in glioblastoma

Clinical study on the role of secretory autophagy protein HMGB1 in the treatment resistance of temozolomide in glioblastoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047776
Enrollment
Unknown
Registered
2021-06-26
Start date
2021-08-03
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

Case series:No

Sponsors

the First Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. More than two pathologists re-read the radiographs together and confirmed the diagnosis as glioma (includingii, Ta and minor grade). 2. The enrolled patients underwent two operations, and the first operation underwent temozolomide standard chemotherapy, and they were provided with corresponding frozen tissue, preoperative and postoperative blood samples (plasma and serum), frozen sections, paraffin samples, tissue microarray, DNA and RNA samples.

Exclusion criteria

Exclusion criteria: Cases with uncertain diagnosis.

Design outcomes

Primary

MeasureTime frame
high mobility group protein;—

Countries

China

Contacts

Public ContactYao Xiaohong

Institute of Pathology and Southwest Cancer Center, Southwest Hospital

yxh15@hotmail.com+86 15923566825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026